Comparing two antibody-drug conjugates for advanced urothelial cancer
Treatments studied
Part of Brain & nervous system, Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial compares two antibody-drug conjugates (a type of targeted therapy that delivers chemotherapy directly to cancer cells) for advanced urothelial cancer. It aims to find a safer and more effective treatment option for patients with this disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older
- You must have advanced urothelial cancer (bladder, ureter, renal pelvis, or urethra) that has spread or cannot be removed with surgery
- You must have already received at least one prior treatment for advanced disease
- You must be in generally good health (able to care for yourself and up and about)
- Your liver, kidneys, and blood counts must be within acceptable levels
- You must not have active brain or spinal cord metastases, serious lung disease, or heart problems
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial studies whether the study medicines SI-B003 alone or together with BL-B01D1 plus SI-B003 can shrink or control advanced cancers that have not responded to standard treatment (or where standard treatment isn’t possible). It also looks at safety and how well the treatment works in people whose cancer can be measured on scans.
This trial is for people with advanced bladder cancer (urothelial cancer) that has spread or can't be removed. It tests a new drug called sacituzumab tirumotecan against standard chemotherapy options to see if it works better.
This trial tests a new targeted drug, BL-M07D1, against standard chemotherapy in people with advanced bladder cancer that has grown after immunotherapy. It may offer a new treatment option for those with a specific protein (HER2) on their cancer cells.
This trial tests a new drug, CA-4948, combined with pembrolizumab (Keytruda) for people with advanced bladder cancer that grew after prior immunotherapy. The goal is to see if this combination can help when standard treatments stop working.
This trial tests a new combination of two drugs—9MW2821 (an antibody-drug conjugate) and Toripalimab (an immunotherapy)—given before and after surgery for muscle-invasive or high-risk urothelial cancer that has not spread. The goal is to see if this combined treatment can improve outcomes.
This study tests two experimental drugs, given alone or together, for advanced urothelial carcinoma (a type of bladder cancer). The goal is to see if they can shrink tumors and slow the cancer's growth.
Hear when a new Bladder Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.